Search research articles
Contact Us
Filters
Showing results (171-180 of 245) with videos related to
Page
of 25
Sort By:
Archives of Internal Medicine
|
June 10, 2009
Continuation of statin treatment and mortality: a note of caution on excessive benefits
Kristian B Filion, Verena Schneider-Lindner, Igor Karp, et al.
Archives of Internal Medicine
|
January 26, 2005
Fluctuating inflammatory markers in patients with stable ischemic heart disease
Peter Bogaty, James M Brophy, Luce Boyer, et al.
Circulation
|
August 11, 2004
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study
Peter Bogaty, James M Brophy, Martin Noel, et al.
Current Drug Safety
|
June 6, 2012
Irritable bowel syndrome and drospirenone-containing oral contraceptives; a comparative-safety study
Steven T Bird, Wei Liu, James M Brophy, et al.
BMC Clinical Pharmacology
|
January 3, 2012
The association between drospirenone and hyperkalemia: a comparative-safety study
Steven T Bird, Salvatore R Pepe, Mahyar Etminan, et al.
The American Journal of Cardiology
|
March 10, 2010
Usefulness of soluble fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes
Héloise Cardinal, James M Brophy, Peter Bogaty, et al.
BMJ (Clinical Research Ed.)
|
May 11, 2017
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michèle Bally, Nandini Dendukuri, Benjamin Rich, et al.
BMC Health Services Research
|
July 11, 2006
The risk of death associated with delayed coronary artery bypass surgery
Boris G Sobolev, Adrian R Levy, Lisa Kuramoto, et al.
The American Journal of Cardiology
|
June 12, 2010
Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs
Christine G St Germaine, Peter Bogaty, Luce Boyer, et al.
Plos One
|
April 13, 2013
Time variability of C-reactive protein: implications for clinical risk stratification
Peter Bogaty, Gilles R Dagenais, Lawrence Joseph, et al.
Page
of 25
Search research articles
Search
Showing results (171-180 of 245) with videos related to
Sort By:
Page
of 25
Archives of Internal Medicine
|
June 10, 2009
Continuation of statin treatment and mortality: a note of caution on excessive benefits
Kristian B Filion, Verena Schneider-Lindner, Igor Karp, et al.
Archives of Internal Medicine
|
January 26, 2005
Fluctuating inflammatory markers in patients with stable ischemic heart disease
Peter Bogaty, James M Brophy, Luce Boyer, et al.
Circulation
|
August 11, 2004
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study
Peter Bogaty, James M Brophy, Martin Noel, et al.
Current Drug Safety
|
June 6, 2012
Irritable bowel syndrome and drospirenone-containing oral contraceptives; a comparative-safety study
Steven T Bird, Wei Liu, James M Brophy, et al.
BMC Clinical Pharmacology
|
January 3, 2012
The association between drospirenone and hyperkalemia: a comparative-safety study
Steven T Bird, Salvatore R Pepe, Mahyar Etminan, et al.
The American Journal of Cardiology
|
March 10, 2010
Usefulness of soluble fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes
Héloise Cardinal, James M Brophy, Peter Bogaty, et al.
BMJ (Clinical Research Ed.)
|
May 11, 2017
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michèle Bally, Nandini Dendukuri, Benjamin Rich, et al.
BMC Health Services Research
|
July 11, 2006
The risk of death associated with delayed coronary artery bypass surgery
Boris G Sobolev, Adrian R Levy, Lisa Kuramoto, et al.
The American Journal of Cardiology
|
June 12, 2010
Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs
Christine G St Germaine, Peter Bogaty, Luce Boyer, et al.
Plos One
|
April 13, 2013
Time variability of C-reactive protein: implications for clinical risk stratification
Peter Bogaty, Gilles R Dagenais, Lawrence Joseph, et al.
Page
of 25